✦ LIBER ✦

Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

✍ Scribed by Moran, M.S.

Book ID: 122450861
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 54 KB
Volume: 21
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(10)79591-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiotherapy concurrent with trastuzumab

Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study

✍ E.A. Perez; Halyard; T. Pisansky; V.J. Suman; A. Dueck; N. Davidson; S. Martino; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Four-Year Follow-Up of Trastuzumab Plus

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

✍ Perez, E. A.; Romond, E. H.; Suman, V. J.; Jeong, J.-H.; Davidson, N. E.; Geyer, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 257 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views